1、他米巴罗汀的合成及其胶囊研制Synthesis and capsule preparation of Tamibarotene他米巴罗汀针对ATRA的耐药性而开发，是对急性早幼粒细胞白血病复发患者具有显著分化诱导能力的药品。该药物显示对ATRA缓解后复发的APL 具有显著有效性，对ATRA应答困难患者的有效性也可期待。开发出该类新型抗白血病药物将具有广泛的市场应用前景。Tamibarotene is a fully synthetic retinoid developed to specifically overcome resistance to ATRA and is currently approved in Japan for treatment of relapsed/refractory acute promyelocytic leukemia (APL). In vitro, Tamibarotene is approximately 10 times more potent than ATRA at causing APL cells to differ
